Adalimumab yielded better outcomes than infliximab in best-corrected visual acuity, retention and other areas among patients with uveitis related to Behçet’s disease, according to findings published in Arthritis & Rheumatology.
“According to the ‘Expert panel recommendations for the use of anti-TNF-alpha drugs in patients with ocular inflammatory disorders,’ published in 2014, anti-TNF therapy with infliximab (good-quality evidence) or adalimumab (moderate-quality evidence) may be considered as the first- or second-line corticosteroid-sparing therapy for
Uncategorized